# Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load

> **NCT05898841** · PHASE4 · COMPLETED · sponsor: **Fundacion SEIMC-GESIDA** · enrollment: 63 (actual)

## Conditions studied

- HIV Infections
- Fatty Liver Disease

## Interventions

- **DRUG:** Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day
- **DRUG:** Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day
- **DRUG:** Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.

## Key facts

- **NCT ID:** NCT05898841
- **Lead sponsor:** Fundacion SEIMC-GESIDA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-26
- **Primary completion:** 2025-07-07
- **Final completion:** 2025-07-07
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05898841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05898841, "Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05898841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*